Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GILD Gilead Sciences Inc

-0.92 (-1.39%)
May 25 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 5,971,046
Bid Price 61.49
Ask Price 69.67
News -
Day High 66.43


52 Week Range


Day Low 65.21
Company Name Stock Ticker Symbol Market Type
Gilead Sciences Inc GILD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.92 -1.39% 65.25 00:00:04
Open Price Low Price High Price Close Price Prev Close
66.38 65.21 66.43 65.68 66.17
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
58,054 5,971,046 $ 65.65 $ 392,003,690 - 64.33 - 87.865
Last Trade Time Type Quantity Stock Price Currency
19:59:06 1 $ 65.65 USD

Gilead Sciences (GILD) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


Gilead Sciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
81.82B 1.25B - 27.12B 5.67B 4.55 14.44
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Gilead Sciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No GILD Message Board. Create One! See More Posts on GILD Message Board See More Message Board Posts

Historical GILD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week67.8268.038365.2167.355,123,961-2.57-3.79%
1 Month65.5068.3764.3366.136,588,914-0.25-0.38%
3 Months72.2876.2164.3369.476,932,199-7.03-9.73%
6 Months75.8987.86564.3374.347,087,591-10.64-14.02%
1 Year79.1287.86564.3375.646,411,822-13.87-17.53%
3 Years69.1089.7457.16571.627,093,036-3.85-5.57%
5 Years67.3089.7456.5670.338,283,624-2.05-3.05%

Gilead Sciences Description

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Your Recent History

Delayed Upgrade Clock